Mesh Bio
A digital health start up that is transforming chronic disease management through predictive analytics.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
* | $3.5m | Series A | |
| Total Funding | 000k | ||
Related Content
Mesh Bio was founded in 2018 by Dr. Andrew Wu, Arsen Batagov, and Melvin Heng. The founders combined their expertise in biomedical technology, data science, and healthcare to address the increasing prevalence of chronic diseases.
Dr. Andrew Wu, the CEO, has over two decades of experience in commercializing biomedical technologies, which has been instrumental in shaping the company's strategic direction. The company's mission is to transform chronic disease management by leveraging technology to enable data-driven, patient-centric care.
Mesh Bio operates in the digital health market, providing a health intelligence platform for healthcare providers. This platform uses predictive analytics and clinical workflow automation to help clinicians manage chronic diseases more effectively. The business model is based on providing this platform as a service to hospitals, clinics, and other healthcare institutions, enabling them to improve patient outcomes and operational efficiency.
The core product is a comprehensive platform that integrates patient data from various sources to provide a holistic view of a patient's health. Its key features include risk stratification, predictive modeling of disease progression, and personalized care recommendations. This allows healthcare providers to identify high-risk patients and intervene early, reducing the costs and complications associated with chronic diseases.
Keywords: digital health, predictive analytics, chronic disease management, health intelligence, clinical decision support, patient-centric care, healthcare technology, metabolic diseases, data-driven healthcare, clinical workflow automation